Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GO4T
|
|||
| Drug Name |
IPH4102
|
|||
| Indication | T-cell lymphoma [ICD-11: 2A90; ICD-10: C81-C86] | Phase 2 | [1] | |
| Company |
Innate Pharma Marseille, France
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MHC class I NK cell receptor 3DL2 (CD158k) | Target Info | Antagonist | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03902184) IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma (TELLOMAK). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.